A Retrospective Analysis of Outcomes in Patients With Hepatorenal Syndrome at Methodist Dallas Medical Center

Part of paid clinical trials in Dallas, Texas.

Sponsor
Methodist Health System
Study ID
NCT06095440
Status
Recruiting
Apply to this trial

Conditions

  • Hepatorenal Syndrome

Eligibility Criteria

Sex
ALL
Age
18 Years - 85 Years
Healthy Volunteers
Not accepted

Interventions

  • Hepatorenal Syndrome outcome in Patients at Methodist Health systems — OTHER
    1.2.1. To perform a retrospective analysis of patients with HRS with the aim of comparing various treatment modalities such as vasoconstrictors, albumin, CRRT, Molecular Adsorbent Recirculating System (MARS), and TIPS.

Study Details

Hepatorenal syndrome (HRS) is a common cause of acute kidney injury (AKI) in patients with liver disease \[1\]. Increased activity and presence of vasodilators such as nitric oxide in cirrhotic patients leads to vasodilation, especially in the splanchnic circulation, resulting in hemodynamic changes that precipitate renal injury \[1\]. Patients may present with elevated serum creatinine (Cr), benign urine sediment, and low urine sodium \[1\].

Key Dates

Start date
May 13, 2023
Status verified
Apr 2026
Primary completion
May 13, 2027
Completion
May 13, 2027

Study Design

Enrollment
500 participants (estimated)

Primary Outcome Measure

Primary Outcome for HRS-AKI patients [ Time Frame: 4 years ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
Liver Institute of Methodist Dallas Medical CenterDallasTexas75203
Alejandro Mejia, MD
[email protected]
214-947-4400
Parvez Mantry, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Dallas, TX

By research site
Liver Institute of Methodist Dallas Medical Center· Dallas, TX

Related Studies